The goal of the Small Animal Bioluminescence Imaging (BLI) Core is provide access to the state of the art IVIS Spectrum (Caliper Life Sciences) imaging system and service participating COBRE investigators. Functions of the core as a service to investigators include assistance and consultation in designing animal studies that utilize molecular imaging, training in use of the imaging equipment, collection and analysis of data. The animal core will also provide assistance in optimizing imaging and other surgical procedures involved pre- and post-imaging. The IVIS Spectrum (Caliper Life Sciences) is the most advanced and newest imaging system that enables investigators to study disease progression, cell trafficking and gene expression in live cell in vivo. The equipment is capable of detecting luminiscence and fluoresence in cells from blue to near infrared wavelength. Additionally, the instrument has the ability of 3D anantomical tomography which when combined with fluorescence or luminiscence can demonstrate the location and source of illumination in vivo. The software provided with the system allows the investigators to import the study results and co-register with Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) images. These unique and advanced features of the equipment will enable investigators to conduct specific studies. This Core apart from serving the COBRE investigators will also serve other investigators at OUHSC and neighboring institutions. Currently, the IVIS Xenogen Spectrum BLI System purchased by OUHSC is the only equipment available on campus and thus makes it availability and utility important for a large number of investigators studying various aspects of human diseases that include oncology, eye, diabetes, immunology, pharmaceuticals etc.

Public Health Relevance

The small animal imaging core will enable investigators participating under the COBRE grant to evaluate tumor progression, metastasis and response to therapy. Funding received by this Core will facilitate advanced molecular imaging that is currently not available at the parent institution.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-02
Application #
8539816
Study Section
Special Emphasis Panel (ZRR1-RI-4)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$208,035
Indirect Cost
$67,472
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113
Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143
Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934
Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74
Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384

Showing the most recent 10 out of 68 publications